Financial Performance - The company's operating revenue for 2024 was CNY 651,883,906.60, a decrease of 2.27% compared to CNY 667,038,998.92 in 2023[17] - Net profit attributable to shareholders for 2024 reached CNY 45,928,802.86, representing a significant increase of 198.50% from CNY 15,386,479.71 in 2023[17] - The net profit after deducting non-recurring gains and losses was CNY 18,446,708.96, up 1,579.33% from CNY 1,098,456.92 in the previous year[17] - The net cash flow from operating activities was CNY 111,572,566.21, down 33.14% from CNY 166,880,943.95 in 2023[17] - Basic earnings per share for 2024 were CNY 0.25, an increase of 212.50% compared to CNY 0.08 in 2023[17] - Total assets at the end of 2024 were CNY 926,469,234.87, a slight decrease of 0.14% from CNY 927,743,602.85 at the end of 2023[17] - Net assets attributable to shareholders decreased by 0.81% to CNY 739,003,677.36 from CNY 745,017,765.57 in 2023[17] - The weighted average return on net assets for 2024 was 6.26%, an increase of 4.19% from 2.07% in 2023[17] Revenue and Profit Trends - The company's total revenue for Q1 was approximately ¥160.43 million, with a decline to ¥139.04 million in Q4, reflecting a decrease of about 13.4% quarter-over-quarter[21] - Net profit attributable to shareholders decreased significantly from ¥27.90 million in Q1 to ¥4.11 million in Q4, indicating a decline of approximately 85.3%[21] - Cardiovascular product revenue decreased by 55.61% to ¥84,210,323.29, while diabetes product revenue increased by 41.17% to ¥474,057,188.28[56] Cash Flow and Investments - The cash flow from operating activities showed volatility, with a net cash inflow of ¥67.71 million in Q3, but a net outflow of ¥2.26 million in Q4[21] - Investment cash inflow increased by 15.24% to ¥521,239,418.32, while investment cash outflow rose by 1.40% to ¥502,242,767.81, leading to a net cash flow from investment activities of ¥18,996,650.51, a significant turnaround from a negative cash flow in the previous year[77] - Financing cash inflow surged by 107.27% to ¥22,799,206.96, while financing cash outflow decreased by 4.61% to ¥67,062,215.78, resulting in a net cash flow from financing activities of -¥44,263,008.82, an improvement of 25.36% compared to the previous year[78] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of CNY 1 per 10 shares to all shareholders, based on a total of 186,913,950 shares[3] - The company plans to distribute a cash dividend of RMB 1.00 per 10 shares (including tax), with a total cash dividend amounting to RMB 18,691,395.00[153] - The cash dividend distribution accounts for 100% of the total profit distribution amount[153] Market Position and Product Development - The core product, Miglitol tablets (Aotianping®), holds the largest market share in China's Miglitol formulation market, with successful bids in 25 provinces as of the reporting period[38] - The company has developed a diverse business model, including self-produced drugs, third-party cooperative drugs, raw materials, and drug promotion services[38] - The company’s self-produced drugs are all included in the 2024 National Medical Insurance Directory, indicating strong market competitiveness and growth potential[44] - The company is committed to continuous innovation and development in the pharmaceutical sector, focusing on chronic disease treatments and gynecological core products[37] Research and Development - R&D expenses rose by 12.92% to ¥15,482,858.58, indicating a focus on innovation and product development[69] - The number of R&D personnel increased by 14.63% from 41 in 2023 to 47 in 2024, with the proportion of R&D staff rising from 9.34% to 11.66%[75] - R&D investment amounted to ¥15,982,858.58 in 2024, representing a 32.36% increase from ¥12,075,151.59 in 2023, with R&D investment as a percentage of operating revenue rising from 1.81% to 2.45%[75] Compliance and Governance - The company has maintained compliance with industry regulations, enhancing its operational integrity and market competitiveness[33] - The company is enhancing its governance structure and management level to ensure effective operation as its scale increases[99] - The company operates independently from its controlling shareholders in terms of business, finance, personnel, and assets, ensuring no major related party transactions[117] Environmental Responsibility - The company has been recognized as an environmentally friendly enterprise by the Sichuan Provincial Department of Ecology and Environment, maintaining compliance with environmental regulations[52] - The company has invested a total of 712,700 yuan in environmental governance and protection in 2024, including an environmental protection tax of 290 yuan[170] - The company has established an environmental self-monitoring plan for 2024, including quarterly and monthly monitoring of wastewater and air emissions[169] Employee and Management Structure - The total number of employees at the end of the reporting period is 403, with 135 in production, 98 in sales, and 54 in technical roles[148] - The company has implemented a performance-based salary system that includes basic salary, performance salary, and benefits[149] - The company has conducted various training programs for employees, including management training and new employee onboarding[152] Investor Relations and Transparency - The company is actively engaging with investors through various communication channels to enhance transparency and information sharing[110] - The company has established a talent strategy, focusing on employee rights and providing various training opportunities for continuous growth[172] - The company has maintained a strong commitment to information disclosure, ensuring timely and accurate updates on its financial status and major events[174]

证券代码：002826 股票简称：易明医药 公告编号：2025-019 西藏易明西雅医药科技股份有限公司 一、本次授权概述 关于提请股东大会授权董事会办理以简易程序向特定对象发行股 票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 西藏易明西雅医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开 第三届董事会第二十三次会议和第三届监事会第二十一次会议，审议通过了《关于提请股 东大会授权董事会办理以简易程序向特定对象发行股票的议案》。 根据《上市公司证券发行注册管理办法》《深圳证券交易所上市公司证券发行上市审 核规则》《深圳证券交易所上市公司证券发行与承销业务实施细则》等相关规定，公司董 事会提请股东大会授权董事会以简易程序向特定对象发行融资总额不超过人民币三亿元 且不超过最近一年末净资产百分之二十的股票，授权期限自公司 2024 年年度股东大会审 议通过之日起至公司 2025 年年度股东大会召开之日止。本议案尚需提交公司 2024 年年度 股东大会审议。现将有关情况公告如下： 二、本次授权具体内容 1、确认公司是否符合以简易程序向特定对象发行股票的条 ...

截至2025年3月28日收盘，易明医药（002826）报收于11.01元，较上周的10.99元上涨0.18%。本周，易 明医药3月28日盘中最高价报11.18元。3月24日盘中最低价报10.25元。易明医药当前最新总市值21.24亿 元，在化学制药板块市值排名143/152，在两市A股市值排名4736/5140。 本周关注点 公司公告汇总 西藏易明西雅医药科技股份有限公司近日收到西藏拉萨经济技术开发区管理委员会拨付的2024年度产业 扶持专项资金10,000,000.00元，占公司2023年度经审计归属于上市公司股东净利润的64.99%。根据《企 业会计准则第16号-政府补助》的规定，公司本次获得的政府补助属于与收益相关的政府补助，与公司 日常经营活动相关，计入2025年度其他收益，具体会计处理以年度审计机构审计结果为准。上述政府补 助预计将增加公司2025年度利润总额10,000,000.00元，最终影响以年度审计机构审计结果为准。本次收 到的产业扶持专项资金为部分金额，最终金额以拉萨经济技术开发区经济发展局的最终考核结果为准， 公司将及时披露后续情况。备查文件包括收款凭证。特此公告。西藏易明西雅医药科技股 ...

证券代码：002826 证券简称：易明医药 公告编号：2025-012 西藏易明西雅医药科技股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、获取补助的基本情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"）近日收到西藏 拉萨经济技术开发区管理委员会拨付的2024年度产业扶持专项资金 10,000,000.00元，占公司2023年度经审计归属于上市公司股东净利润的 64.99%。 二、补助的类型及其对公司的影响 1、补助的类型 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相 关的政府补助，是指除与资产相关的政府补助之外的政府补助。 公司本次获得的政府补助属于与收益相关的政府补助。 2、补助的确认、计量 计结果为准。 3、补助对上市公司的影响 上述政府补助预计将增加公司2025年度利润总额10,000,000.00元，最终影 响以年度审计机构审计结果为准。 4、风险提示和其他说明 本次收到的产业扶持专项资金为部分金额，最终金额 ...

证券代码：002826 证券简称：易明医药 公告编号：2025-011 西藏易明西雅医药科技股份有限公司 关于公司董事、持有 5%以上股东减持股份的预披露公告 董事、持有 5%以上股东周战先生和董事许可先生保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有西藏易明西雅医药科技股份有限公司（以下简称"公司"）股份 14,361,702 股（占公司总股本比例的 7.5319%，占剔除公司回购专用账户股份后 总股本比例的 7.6836%）的董事、持股 5%以上股东周战先生，计划自本公告披露 之日起 15 个交易日后的 3 个月内，以集中竞价方式或大宗交易方式减持公司股 份不超过 3,590,000 股（不超过公司总股本比例的 1.8828%，不超过剔除公司回 购专用账户股份后总股本比例的 1.9207%）。 持有公司股份 1,215,447 股（占公司总股本的 0.6374%，占剔除公司回购专 用账户股份后总股本比例的 0.6503%）的董事许可先生，计划自本公告披露之日 起 15 个交易日后的 3 ...

证券代码：002826 股票简称：易明医药 公告编号：2025-010 西藏易明西雅医药科技股份有限公司 关于控股股东部分股份提前解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"公司"）近日接到控股股 东、实际控制人高帆先生的通知，获悉高帆先生其质押的股份提前办理了解除质 押手续，具体事项如下： | 股东 | 是否为控股股 东或第一大股 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总股 本比例 | 起始日 | | 解除日期 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 东及其一致行 | （股） | （%） | （%） | | | | | | | | 动人 | | | | | | | | | | 高帆 | 是 | 2,450,000 | 5.02 | 1.28 | 年 2024 | 月 6 | 年 2025 2 | 月 | 华西证券股 | | | | | | | 17 日 | ...

证券代码：002826 证券简称：易明医药 公告编号：2025-009 3、首次授予限制性股票的授予数量：344.00万股，占首次授予日公司总股 本的1.80%； 4、首次授予限制性股票的授予价格：6.45元/股； 5、首次授予限制性股票的授予登记人数：33 人； 西藏易明西雅医药科技股份有限公司 关于 2024 年限制性股票激励计划首次授予登记完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、首次授予限制性股票的授予日：2025年1月7日； 2、首次授予的限制性股票登记完成日：2025年2月26日； 大会授权董事会办理股权激励相关事宜的议案》，相关议案经董事会薪酬与考核 委员会审议通过，北京植德律师事务所出具了法律意见书。 6、限制性股票的来源：公司从二级市场回购的本公司人民币A股普通股股 票。 根据《上市公司股权激励管理办法》及深圳证券交易所、中国证券登记结算 有限责任公司深圳分公司的有关规定，西藏易明西雅医药科技股份有限公司（以 下简称"公司"）完成了2024年限制性股票激励计划（以下简称"本次激励计划"） 的首次授予登记工 ...

通过对2024年业绩预增50%以上的个股走势进行统计发现，预告发布后当日股价上涨的占比66.36%，股 价发布当日股价涨停的有22家。 预告发布后5日股价上涨的占比69.55%。 证券时报网讯，易明医药(002826)1月22日发布2024年业绩预增公告，预计实现净利润为3565.00万元 ~5124.00万元，净利润同比增长131.70%~233.02%。 证券时报•数据宝统计显示，易明医药今日收于10.97元，下跌3.26%，日换手率为2.66%，成交额为 5171.03万元，近5日上涨5.18%。 ...

Financial Performance Projections - The estimated net profit attributable to shareholders for 2024 is projected to be between 35.65 million and 51.24 million yuan, representing a year-on-year growth of 131.70% to 233.02% compared to 15.39 million yuan in the previous year [2]. - The net profit after deducting non-recurring gains and losses is expected to be between 13.32 million and 19.14 million yuan, indicating a significant increase of 1,112.56% to 1,642.38% from 1.10 million yuan in the same period last year [2]. - Basic earnings per share are forecasted to be between 0.19 yuan and 0.28 yuan, up from 0.08 yuan per share in the previous year [2]. Factors Influencing Performance - The primary reason for the increase in performance is the absence of goodwill impairment losses, which were 19.80 million yuan in the previous year, resulting in a decrease in asset impairment losses [3]. - The company received 28.19 million yuan in industry support funds for 2023, which is an increase of 16.27 million yuan compared to the previous year, contributing to non-recurring gains [3].

西藏易明西雅医药科技股份有限公司 2024 年限制性股票激励计划首次授予激励对象名单 （授予日） 西藏易明西雅医药科技股份有限公司 2、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均累 计未超过公司股本总额的 1%。公司全部在有效期内的股权激励计划所涉及的标的股票总数 累计未超过公司股本总额的 10%。 3、上述合计数与各明细数直接相加之和在尾数上如有差异，系百分比结果四舍五入所 致。 4、预留部分的激励对象应当在本激励计划经股东大会审议通过后 12 个月内确定,经董 事会提出、监事会发表明确意见、律师发表专业意见并出具法律意见书后，公司在指定网站 按要求及时准确披露激励对象相关信息。 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 高勇 | 核心管理/业务人员 | | 2 | 狄国伟 | 核心管理/业务人员 | 二、 首次授予的公司核心管理/业务人员名单 | 3 | 杨云峰 | 核心管理/业务人员 | | --- | --- | --- | | 4 | 刘健 | 核心管理/业务人员 | | 5 | 王燕 | 核心管理/业务人员 | | 6 | 高 ...